What prophylactic dose of ruxolitinib should be used to prevent graft‑versus‑host disease (GVHD) in adult patients undergoing hematopoietic stem cell transplantation (HSCT) with normal renal and hepatic function?

Ruxolitinib Prophylactic Dose for GVHD Prevention in HSCT

For GVHD prophylaxis in adult patients undergoing hematopoietic stem cell transplantation with normal renal and hepatic function, initiate ruxolitinib at 5 mg orally twice daily starting on day +1 post-transplant, continue through day +60, then taper to day +90 in the absence of grade II-IV acute GVHD.

Evidence-Based Dosing Algorithm

The prophylactic dosing of ruxolitinib for GVHD prevention differs fundamentally from treatment dosing for established steroid-refractory disease. While FDA approval and NCCN guidelines 111 address ruxolitinib for treatment of steroid-refractory acute GVHD at 5 mg twice daily (with optional escalation to 10 mg twice daily), the prophylactic context requires different considerations.

Standard Prophylactic Regimen

The most robust evidence supports:

• Starting dose: 5 mg orally twice daily for patients ≥50 kg; 5 mg once daily for patients <50 kg
• Initiation timing: Day +1 post-transplant
• Duration: Continue through day +60, then taper to discontinuation by day +90 if no grade II-IV acute GVHD develops
• Context: Used within a backbone of antithymocyte globulin, calcineurin inhibitor, and short-course methotrexate

This regimen demonstrated remarkable efficacy in the largest randomized controlled trial 2, reducing grade II-IV acute GVHD by day 100 from 36.9% to 6.8% (subdistribution hazard ratio 0.15, p<0.0001) in haploidentical HSCT. The study enrolled 206 patients and showed manageable toxicity with this low-dose approach.

Alternative Prophylactic Strategies

Calcineurin-free approach: A multicenter phase II trial 3 compared post-transplant cyclophosphamide (PTCy) plus ruxolitinib versus PTCy-tacrolimus-mycophenolate. The ruxolitinib arm used:

• Dose: 5 mg three times daily during conditioning and days +5 to +21, then 5 mg twice daily from day +22 to +150
• Results: Grade II-IV acute GVHD at 12.9% versus 21.2% (met noninferiority), with superior safety profile including reduced acute kidney injury (1.6% vs 12.1%, p=0.02) and endothelial complications (1.6% vs 13.6%, p=0.01)

For CNI-intolerant patients: When calcineurin inhibitors must be replaced, ruxolitinib 5-10 mg twice daily can substitute 4, though this represents rescue prophylaxis rather than primary prevention.

Critical Timing Considerations

Emerging data suggests delayed initiation may be superior in certain contexts. A recent comparative study 5 found that delaying ruxolitinib until neutrophil engraftment (median day +13) versus immediate day +1 initiation resulted in:

• Lower grade II-IV acute GVHD (10.0% vs 42.1%, p=0.031)
• Reduced CMV reactivation (35.0% vs 73.7%, p=0.025)
• Superior 2-year overall survival (90.0% vs 57.9%, p=0.012)

However, this was a small single-center study (n=39) with ATG-based conditioning, and requires validation before changing practice. Until confirmed by larger trials, day +1 initiation remains standard based on the phase 3 evidence 2.

Weight-Based Dosing

• Patients ≥50 kg: 5 mg orally twice daily
• Patients <50 kg: 5 mg orally once daily

This weight-based adjustment was used in the pivotal prophylaxis trial 2 and reflects pharmacokinetic considerations in smaller patients.

Common Pitfalls and Monitoring

Do not confuse prophylactic with treatment dosing. The FDA-approved treatment dose for steroid-refractory acute GVHD 11 starts at 5 mg twice daily with optional escalation to 10 mg twice daily. Prophylactic dosing maintains the lower 5 mg twice daily dose without routine escalation.

Key toxicities to monitor:

• Hematologic: Thrombocytopenia, neutropenia, and anemia are most common 2. In the prophylaxis trial, grade 3-4 thrombocytopenia occurred in 17%, neutropenia in 14%, and anemia in 12%.
• Infectious complications: CMV reactivation occurred in 33% of patients receiving ruxolitinib for treatment 1. In prophylaxis studies, rates varied from 15-40% 246.
• Avoid abrupt discontinuation: Taper gradually from day +60 to +90 to prevent rebound GVHD.

Drug interactions: Ruxolitinib is metabolized by CYP3A4 77. Strong CYP3A4 inhibitors (e.g., ketoconazole) increase ruxolitinib exposure by 91%, while inducers (e.g., rifampin) decrease it by 61%. Adjust dosing or avoid concurrent use when possible.

Context-Specific Modifications

Haploidentical transplantation: The strongest prophylaxis data comes from haploidentical settings 26, where ruxolitinib combined with ATG-based regimens achieved grade II-IV acute GVHD rates of 6.8-19.2%.

Aplastic anemia patients: A phase II study 8 in peripheral blood stem cell transplantation for aplastic anemia used the same 5 mg twice daily dosing for 3 months post-transplant, demonstrating safety and efficacy with rapid CD4+ Treg recovery.

Post-transplant cyclophosphamide platforms: When using PTCy-based GVHD prophylaxis, ruxolitinib can be initiated at 5 mg three times daily during conditioning and early post-transplant period, then reduced to twice daily dosing 36.

Distinguishing Prophylaxis from Treatment

The NCCN guidelines 111 and FDA labeling 77 focus on ruxolitinib for treatment of established steroid-refractory GVHD, not prophylaxis. The treatment context uses 5 mg twice daily as a starting dose with potential escalation to 10 mg twice daily based on response and absence of cytopenias. In contrast, prophylactic use maintains the lower 5 mg twice daily dose throughout the prevention period, with tapering rather than escalation as the planned trajectory.

The prophylactic approach is supported by multiple recent trials 2386 demonstrating that lower, fixed dosing effectively prevents GVHD when integrated into comprehensive immunosuppressive regimens, rather than treating established disease.